市場調查報告書

中國的多烯卵磷脂市場分析

Investigation Report on China's Polyene Phosphatidylcholine Market, 2019-2023

出版商 China Research and Intelligence 商品編碼 907272
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的多烯卵磷脂市場分析 Investigation Report on China's Polyene Phosphatidylcholine Market, 2019-2023
出版日期: 2019年08月20日內容資訊: 英文 30 Pages
簡介

本報告提供中國國內的多烯卵磷脂市場相關分析,產品的概要、功效和授權情形,整體市場規模趨勢預測 (過去、今後5年份),市場價格的變化及預測,主要企業的簡介與市場佔有率等資訊彙整,為您概述為以下內容。

第1章 多烯卵磷脂的相關概念

  • 多烯卵磷脂的適應症
  • 中國的多烯卵磷脂市場發展
  • 中國國內的基因改造促濾泡素β的相關專利和政府核准趨勢

第2章 中國國內的多烯卵磷脂的銷售量

  • 銷售額
  • 銷售量
  • 多烯卵磷脂的按銷售額:劑型 (過去5年份)

第3章 中國的多烯卵磷脂主要製造商分析

  • 主要廠商的市場佔有率分析
  • A. Nattermann & Cie. GmbH
  • Sanofi
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
  • Sanofi (Beijing) Pharmaceutical Co., Ltd.

第4章 多烯卵磷脂國內價格趨勢

  • A. Nattermann & Cie. GmbH
  • Sanofi
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd. (Tianxing)
  • Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
  • Sanofi (Beijing) Pharmaceutical Co., Ltd. (Essentiale Forte N)

第5章 中國的多烯卵磷脂市場未來展望

  • 對市場的影響要素
    • 有利的要素
    • 不利因素
  • 市場規模的預測 (今後5年份)
  • 市場趨勢的預測 (今後5年份)
目錄
Product Code: 1908400

Description

According to statistics, at the end of 2018, there were about 86 million hepatitis B carriers and about 10 million hepatitis C carriers in China. In 2014, the prevalence of hepatitis B surface antigen in children under five years of age decreased to 0.32%, achieving the WHO's hepatitis B control goal for the west Pacific area ahead of schedule. In 2018, the reported incidence of hepatitis A in China decreased to 1.17/100,000, the lowest level in history. But in the context of long-term accumulation of hepatitis B and hepatitis C carriers, large number of hepatitis B and hepatitis C patients, and lack of public awareness, the prevention and control of viral hepatitis remains an arduous task.

According to CRI, China has a high incidence of viral hepatitis. As a result, the hepatoprotective drug market maintains a high growth rate. Polyene Phosphatidylcholine is one of the best-selling hepatoprotective drugs to hospitals. It is refined from soybean lecithin. Its main active ingredient is diacylphospholipidcholine that accounts for about 52%. As a substance that repairs damaged liver cell membranes/organelle membranes and restores membrane function, diacylphospholipidcholine can provide the human body with endogenous phospholipids and nutritional supplements. In China, Polyene Phosphatidylcholine is used to treat liver diseases such as hepatitis, chronic hepatitis, hepatonecrosis, cirrhosis, hepatic coma (including prodromal hepatic coma) and fatty liver (also seen in diabetics). It also applies to the treatment of cholestasis and toxicosis, the prevention of recurrence of gallstones, the treatment before and after surgeries, especially hepatobiliary surgeries, and gestoses including vomiting, psoriasis, neurodermatitis and radiation syndromes.

The brand-name drug of Polyene Phosphatidylcholine is Essentiale by Sanofi. It is difficult to copy the brand-name drug because it has complex sources of active pharmaceutical ingredient and preparation process. In 2005, Chinese enterprise Haisco Pharmaceutical Group Co., Ltd. Launched generic Polyene Phosphatidylcholine. Later, some other enterprises launched their generic products.

According to CRI's market survey, the sales value of Polyene Phosphatidylcholine has been growing since the drug was launched in China. In recent years, the growth of the sales value is slowing down. In 2017, the sales value of Polyene Phosphatidylcholine in China was about CNY 555 million, representing a CAGR of about 1.40% from 2013 to 2017. By sales value, Chengdu Tiantaishan Pharmaceutical Co., Ltd. Took up the largest market share of over 70%; by sales volume, Sanofi (Beijing) Pharmaceutical Co., Ltd. Took up the largest market share of over 60%.

It is expected that the number of patients with viral hepatitis in China will stay between 90 million and 100 million from 2019 to 2023. At the same time, with the development of China's economy, medical services will become more affordable. China's Polyene Phosphatidylcholine market still has certain growth potential.

Topics covered:

  • Incidence of viral hepatitis in China
  • Development of Polyene Phosphatidylcholine in China
  • Major Polyene Phosphatidylcholine manufacturers in China and competition on China's Polyene Phosphatidylcholine market
  • Retail prices of Polyene Phosphatidylcholine in China
  • Prospect of China's Polyene Phosphatidylcholine market from 2019 to 2023

Table of Contents

1 Relevant Concepts of Polyene Phosphatidylcholine

  • 1.1 Indications for Polyene Phosphatidylcholine
  • 1.2 Development of Polyene Phosphatidylcholine in China
  • 1.3 Patents and Government Approval on Polyene Phosphatidylcholine in China

2 Sales of Polyene Phosphatidylcholine in China, 2013-2017

  • 2.1 Sales Value
  • 2.2 Sales volume
  • 2.3 Sales of Polyene Phosphatidylcholine by Dosage Form in China, 2013-2017

3 Analysis on Major Polyene Phosphatidylcholine Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Polyene Phosphatidylcholine Manufacturers
  • 3.2 A. Nattermann & Cie. GmbH
  • 3.3 Sanofi
  • 3.4 Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • 3.5 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
  • 3.6 Sanofi (Beijing) Pharmaceutical Co., Ltd.

4 Prices of Polyene Phosphatidylcholine in China, 2017-2018

  • 4.1 A. Nattermann & Cie. GmbH
  • 4.2 Sanofi
  • 4.3 Chengdu Tiantaishan Pharmaceutical Co., Ltd. (Tianxing)
  • 4.4 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
  • 4.5 Sanofi (Beijing) Pharmaceutical Co., Ltd. (Essentiale Forte N)

5 Prospect of China's Polyene Phosphatidylcholine Market, 2019-2023

  • 5.1 Factors Influencing Development of China's Polyene Phosphatidylcholine Market
    • 5.1.1 Favorable Factors
    • 5.1.2 Unfavorable Factors
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

Selected Charts

  • Chart Patents on Polyene Phosphatidylcholine in China
  • Chart Government Approval on Polyene Phosphatidylcholine in China
  • Chart Sales of Polyene Phosphatidylcholine in China, 2013-2017
  • Chart Sales Value of Polyene Phosphatidylcholine in Parts of China, 2013-2017
  • Chart Sales Volume of Polyene Phosphatidylcholine in China, 2013-2017
  • Chart Sales Volume of Polyene Phosphatidylcholine in Parts of China, 2013-2017
  • Chart Sales Value of Polyene Phosphatidylcholine Injections in China, 2013-2017
  • Chart Sales Value of Polyene Phosphatidylcholine Capsules in China, 2013-2017
  • Chart Market Share of Top 5 Polyene Phosphatidylcholine Manufacturers by Sales Value, 2013-2017
  • Chart Market Share of Top 5 Polyene Phosphatidylcholine Manufacturers by Sales Volume, 2013-2017
  • Chart Sales Value of Polyene Phosphatidylcholine by A. Nattermann & Cie. GmbH in China, 2013-2017
  • Chart Sales Value of Polyene Phosphatidylcholine by Sanofi in China, 2013-2017
  • Chart Sales Value of Polyene Phosphatidylcholine by Chengdu Tiantaishan Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Volume of Polyene Phosphatidylcholine by Chengdu Tiantaishan Pharmaceutical Co., Ltd., 2013-2017
  • Chart Prices of Polyene Phosphatidylcholine by A. Nattermann & Cie. GmbH in Parts of China, 2017-2018
  • Chart Prices of Polyene Phosphatidylcholine by Sanofi in Parts of China, 2017-2018
  • Chart Prices of Polyene Phosphatidylcholine by Chengdu Tiantaishan Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
  • Chart Forecast on Sales Value of Polyene Phosphatidylcholine in China, 2019-2023
Back to Top